According to Zhitong Finance APP, CStone Pharma-B (HKEX: 02616) rose nearly 7%, up 6.81% as of press time to HK$5.49, with turnover of HK$35.1891 million.

On the news front, the latest clinical data for the company's core asset CS2009 (a PD-1/VEGF/CTLA-4 trispecific antibody) will be disclosed in two rapid oral presentations at the European Society for Medical Oncology (ESMO) Annual Meeting to be held in October 2026.

In addition, the company's Chief Executive Officer, President of R&D, and Executive Director Yang Jianxin purchased a total of 496,000 shares of the company in the open market with personal funds between September 17 and 22, for a total consideration of more than HK$2.7 million.

It is reported that since assuming the role of Chief Executive Officer in August 2022, Dr. Yang Jianxin has cumulatively purchased more than 14.21 million shares of the company in the open market. This share purchase fully demonstrates Dr. Yang's long-term commitment to the company and his firm confidence in the company's future business prospects.